person · Reporting owner

KINDLER JEFFREY B

Disclosed activity across 8 companies

Tapewire entity: 16924
SEC CIK: 0001174454

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
PERRIGO Co plcPRGO · Entity 4516	Director	May 14, 2025	May 16, 2025
PRECIGEN, INC.PGEN · Entity 4356	Director	August 26, 2026	August 28, 2026
Praxis Precision Medicines, Inc.PRAX · Entity 3538	Director	June 10, 2026	June 12, 2026
SIGA TECHNOLOGIES INCSIGA · Entity 6205	Director	May 21, 2020	May 22, 2020
vTv Therapeutics Inc.VTVT · Entity 6614	Director	June 11, 2020	June 15, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

PERRIGO Co plc

Report date May 14, 2025 · Filed May 16, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	10,559	Ending reported balance After 2025-05-14 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2025-05-14 · Exercise / conversion · Acquired 9,904 · Balance 15,313 Row 2 · 2025-05-14 · Tax withholding · Disposed 4,754 · Balance 10,559
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	7,305	Reported balance After 2025-05-14 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-05-14 · Grant · Acquired 7,305 · Balance 7,305 F1: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2026.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2025-05-14 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-05-14 · Exercise / conversion · Disposed 9,904 · Balance 0 F1: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2025.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share.

F2: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2026.

F3: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2025.

PRECIGEN, INC.

Report date August 26, 2026 · Filed August 28, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	17,100	Reported balance After 2026-08-26 transaction · row 1 1 source row Row 1 · 2026-08-26 · Sale · Disposed 185,000 · Balance 17,100 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.38 to $7.59, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.38 to $7.59, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

Praxis Precision Medicines, Inc.

Report date June 10, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,537	Reported balance After 2026-06-10 transaction · row 1 1 source row Row 1 · 2026-06-10 · Grant · Acquired 1,371 · Balance 2,537 F1: Mr. Kindler was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $240.66 · Expires 2036-06-10	Direct	648	Reported balance After 2026-06-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-10 · Grant · Acquired 648 · Balance 648 F2: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Mr. Kindler was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

F2: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.

SIGA TECHNOLOGIES INC

Report date May 21, 2020 · Filed May 22, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, Par Value $.0001 Per ShareSEC Table I · non-derivative	Direct	127,339	Reported balance After 2020-05-21 transaction · row 1 1 source row Row 1 · 2020-05-21 · Exercise / conversion · Acquired 15,000 · Balance 127,339
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-05-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-05-21 · Exercise / conversion · Disposed 15,000 · Balance 0 F1: Each restricted stock unit ("RSU") converts into one share of common stock of SIGA Technologies, Inc. on a one for one basis. F2: The RSUs were granted on May 21, 2019, and vested on the first anniversary of such date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") converts into one share of common stock of SIGA Technologies, Inc. on a one for one basis.

F2: The RSUs were granted on May 21, 2019, and vested on the first anniversary of such date.

vTv Therapeutics Inc.

Report date June 11, 2020 · Filed June 15, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 · Expires 2030-06-11	Direct	78,121	Reported balance After 2020-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-06-11 · Grant · Acquired 15,000 · Balance 78,121 F1: The option vests in monthly equal installments over the three year period beginning on June 11, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in monthly equal installments over the three year period beginning on June 11, 2020.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

PFIZER INC

Report date December 15, 2010 · Filed December 17, 2010

Section 16 reporting ended · disclosed 2010-12-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Phantom Stock Units SSPSEC Table II · derivative / convertible security	Direct	62,194	Reported balance After 2010-12-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2010-12-15 · Grant · Acquired 261 · Balance 62,194 F1: Each unit represents one phantom share of common stock. F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Filing footnotes · ownership attribution and instrument terms

F1: Each unit represents one phantom share of common stock.

F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

PPD, Inc.

Report date December 08, 2021 · Filed December 08, 2021

Section 16 reporting ended · disclosed 2021-12-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2021-12-08 transaction · row 1 1 source row Row 1 · 2021-12-08 · Disposition to issuer · Disposed 99,487 · Balance 0 F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2: Includes 2,164 shares of common stock subject to a restricted stock unit grant (the "RSUs") which provided for vesting on the earlier of the one-year anniversary of the grant date and the date of the next regularly scheduled annual meeting of stockholders of the Issuer. At the effective time of the Merger, the RSUs were canceled and converted into the right to receive an amount of cash equal to the Merger Consideration (as defined below) multiplied by the number of restricted stock units being so canceled and converted. F3: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration").
Common StockSEC Table I · non-derivative	IndirectBy Trust	0	Reported balance After 2021-12-08 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2021-12-08 · Disposition to issuer · Disposed 18,500 · Balance 0 F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2: Includes 2,164 shares of common stock subject to a restricted stock unit grant (the "RSUs") which provided for vesting on the earlier of the one-year anniversary of the grant date and the date of the next regularly scheduled annual meeting of stockholders of the Issuer. At the effective time of the Merger, the RSUs were canceled and converted into the right to receive an amount of cash equal to the Merger Consideration (as defined below) multiplied by the number of restricted stock units being so canceled and converted. F3: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration").

Filing footnotes · ownership attribution and instrument terms

F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger").

F2: Includes 2,164 shares of common stock subject to a restricted stock unit grant (the "RSUs") which provided for vesting on the earlier of the one-year anniversary of the grant date and the date of the next regularly scheduled annual meeting of stockholders of the Issuer. At the effective time of the Merger, the RSUs were canceled and converted into the right to receive an amount of cash equal to the Merger Consideration (as defined below) multiplied by the number of restricted stock units being so canceled and converted.

F3: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration").

Terns Pharmaceuticals, Inc.

Report date May 05, 2026 · Filed May 05, 2026

Section 16 reporting ended · disclosed 2026-05-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.82	Direct	Reported balance After 2026-05-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-05 · Disposition to issuer · Disposed 32,000 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.10	Direct	Reported balance After 2026-05-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-05 · Disposition to issuer · Disposed 45,000 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46	Direct	Reported balance After 2026-05-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-05 · Disposition to issuer · Disposed 10,657 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.85	Direct	Reported balance After 2026-05-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-05 · Disposition to issuer · Disposed 4,676 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.99	Direct	Reported balance After 2026-05-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-05-05 · Disposition to issuer · Disposed 32,000 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.24	Direct	Reported balance After 2026-05-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-05-05 · Disposition to issuer · Disposed 28,475 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.72	Direct	Reported balance After 2026-05-05 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-05-05 · Disposition to issuer · Disposed 22,000 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.05	Direct	Reported balance After 2026-05-05 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-05-05 · Disposition to issuer · Disposed 32,000 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.60	Direct	Reported balance After 2026-05-05 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-05-05 · Disposition to issuer · Disposed 1,697 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 17, 2023 Filed May 19, 2023 18:39 UTC	PERRIGO Co plc PRGO · Entity 4516	Tax withholdingOrdinary Shares	3,734	$32.86	$122,699.24	Disclosure SEC source: 0001585364-23-000098 · wf-form4_168452153521332.xml · nonDerivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,450 Read SEC document
May 17, 2023 Filed May 19, 2023 18:39 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionOrdinary Shares	7,778	$32.86	$255,585.08	Disclosure SEC source: 0001585364-23-000098 · wf-form4_168452153521332.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of service-based restricted stock units granted on 17 May 2022. Read SEC document
May 15, 2023 Filed May 17, 2023 19:40 UTC	PERRIGO Co plc PRGO · Entity 4516	GrantRestricted Stock Units · Derivative	8,764	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-23-000074 · wf-form4_168435242824746.xml · derivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,764 Underlying: Ordinary Shares · 8,764 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 15 May 2024. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 15 May 2024. Read SEC document
March 09, 2023 Filed Mar 13, 2023 21:04 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantOption to Purchase Common Stock (Right to Buy) · Derivative	125,489	$0.00 Strike: $1.17	$0.00	Disclosure SEC source: 0000950103-23-004009 · dp190524_4-kindler.xml · derivative · entry 3 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,489 Underlying: Common Stock · 125,489 shares Expires 2033-03-09 Read SEC document
March 09, 2023 Filed Mar 13, 2023 21:04 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantRestricted Stock Units · Derivative	106,837	$0.00	$0.00	Disclosure SEC source: 0000950103-23-004009 · dp190524_4-kindler.xml · derivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,837 Underlying: Common Stock · 106,837 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs vested in full on March 9, 2024. F3 · derivative.expiration_date: The RSUs vested in full on March 9, 2024. Read SEC document
March 09, 2023 Filed Mar 13, 2023 21:04 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantCommon Stock	58,974	$1.17	$68,999.58	Disclosure SEC source: 0000950103-23-004009 · dp190524_4-kindler.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,961 F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $69,000. Read SEC document
February 22, 2023 Filed Feb 25, 2023 01:12 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionRestricted Stock Units · Derivative	61,576	$0.00	$0.00	Disclosure SEC source: 0000950103-23-003032 · dp189563_4-kindler.xml · derivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 61,576 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F2 · derivative.exercise_date: The RSUs vested in full on February 22, 2023. F2 · derivative.expiration_date: The RSUs vested in full on February 22, 2023. Read SEC document
February 22, 2023 Filed Feb 25, 2023 01:12 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionCommon Stock	61,576	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-23-003032 · dp189563_4-kindler.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document
August 11, 2022 Filed Aug 15, 2022 22:28 UTC	PRECIGEN, INC. PGEN · Entity 4356	SaleCommon Stock	50,000	$2.30	$115,000.00	Disclosure SEC source: 0000950103-22-014033 · dp178706_4-kindler.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,411 F1 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.3000 to $2.3250, inclusive. The reporting person undertakes to provide to any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth above. Read SEC document
June 16, 2022 Filed Jun 22, 2022 01:00 UTC	Terns Pharmaceuticals, Inc. TERN · Entity 49595	GrantStock Option (Right to Buy) · Derivative	32,000	$0.00 Strike: $1.82	$0.00	Disclosure SEC source: 0001562180-22-005264 · primarydocument.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: The option will vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant. Read SEC document
May 17, 2022 Filed May 19, 2022 17:52 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionRestricted Stock Units · Derivative	6,599	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-22-000051 · wf-form4_165298273556605.xml · derivative · entry 4 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,599 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · kind: Vesting of service-based restricted stock units granted on 17 May 2021. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 17 May 2022. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 17 May 2022. Read SEC document
May 17, 2022 Filed May 19, 2022 17:52 UTC	PERRIGO Co plc PRGO · Entity 4516	GrantRestricted Stock Units · Derivative	7,778	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-22-000051 · wf-form4_165298273556605.xml · derivative · entry 3 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,778 Underlying: Ordinary Shares · 7,778 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 17 May 2023. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 17 May 2023. Read SEC document
May 17, 2022 Filed May 19, 2022 17:52 UTC	PERRIGO Co plc PRGO · Entity 4516	Tax withholdingOrdinary Shares	3,168	$38.57	$122,189.76	Disclosure SEC source: 0001585364-22-000051 · wf-form4_165298273556605.xml · nonDerivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,406 Read SEC document
May 17, 2022 Filed May 19, 2022 17:52 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionOrdinary Shares	6,599	$38.57	$254,523.43	Disclosure SEC source: 0001585364-22-000051 · wf-form4_165298273556605.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of service-based restricted stock units granted on 17 May 2021. Read SEC document
March 25, 2022 Filed Mar 29, 2022 21:07 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionRestricted Stock Units · Derivative	16,212	$0.00	$0.00	Disclosure SEC source: 0000950103-22-005409 · dp170035_4-kindler.xml · derivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,212 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F2 · derivative.exercise_date: The RSUs vested in full on March 25, 2022. F2 · derivative.expiration_date: The RSUs vested in full on March 25, 2022. Read SEC document
March 25, 2022 Filed Mar 29, 2022 21:07 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionCommon Stock	16,212	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-22-005409 · dp170035_4-kindler.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,411 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document
February 22, 2022 Filed Feb 24, 2022 22:44 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantOption to Purchase Common Stock (Right to Buy) · Derivative	83,189	$0.00 Strike: $2.03	$0.00	Disclosure SEC source: 0000950103-22-003218 · dp167778_4-kindler.xml · derivative · entry 3 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,189 Underlying: Common Stock · 83,189 shares Expires 2032-02-22 Read SEC document
February 22, 2022 Filed Feb 24, 2022 22:44 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantRestricted Stock Units · Derivative	61,576	$0.00	$0.00	Disclosure SEC source: 0000950103-22-003218 · dp167778_4-kindler.xml · derivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,576 Underlying: Common Stock · 61,576 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ('RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs vest in full on February 22, 2023. F3 · derivative.expiration_date: The RSUs vest in full on February 22, 2023. Read SEC document
February 22, 2022 Filed Feb 24, 2022 22:44 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantCommon Stock	33,990	$2.03	$68,999.70	Disclosure SEC source: 0000950103-22-003218 · dp167778_4-kindler.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,199 F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $69,000. Read SEC document
December 08, 2021 Filed Dec 8, 2021 21:39 UTC	PPD, Inc. PPD · Entity 15247	Disposition to issuerCommon Stock	18,500	$47.50	$878,750.00	Disclosure SEC source: 0001437749-21-028111 · rdgdoc.xml · nonDerivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · kind: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2 · price: Includes 2,164 shares of common stock subject to a restricted stock unit grant (the "RSUs") which provided for vesting on the earlier of the one-year anniversary of the grant date and the date of the next regularly scheduled annual meeting of stockholders of the Issuer. At the effective time of the Merger, the RSUs were canceled and converted into the right to receive an amount of cash equal to the Merger Consideration (as defined below) multiplied by the number of restricted stock units being so canceled and converted. F3 · price: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration"). Read SEC document
December 08, 2021 Filed Dec 8, 2021 21:39 UTC	PPD, Inc. PPD · Entity 15247	Disposition to issuerCommon Stock	99,487	$47.50	$4,725,632.50	Disclosure SEC source: 0001437749-21-028111 · rdgdoc.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2 · shares: Includes 2,164 shares of common stock subject to a restricted stock unit grant (the "RSUs") which provided for vesting on the earlier of the one-year anniversary of the grant date and the date of the next regularly scheduled annual meeting of stockholders of the Issuer. At the effective time of the Merger, the RSUs were canceled and converted into the right to receive an amount of cash equal to the Merger Consideration (as defined below) multiplied by the number of restricted stock units being so canceled and converted. F2 · price: Includes 2,164 shares of common stock subject to a restricted stock unit grant (the "RSUs") which provided for vesting on the earlier of the one-year anniversary of the grant date and the date of the next regularly scheduled annual meeting of stockholders of the Issuer. At the effective time of the Merger, the RSUs were canceled and converted into the right to receive an amount of cash equal to the Merger Consideration (as defined below) multiplied by the number of restricted stock units being so canceled and converted. F3 · price: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration"). Read SEC document
September 28, 2021 Filed Oct 1, 2021 01:17 UTC	Terns Pharmaceuticals, Inc. TERN · Entity 49595	GrantStock Option (Right to Buy) · Derivative	22,000	$0.00 Strike: $10.72	$0.00	Disclosure SEC source: 0000899243-21-038548 · doc4.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2031-09-28 F1 · derivative.exercise_date: 1/3rd of the shares subject to the option vest on the first anniversary measured from September 28, 2021 (the "Vesting Commencement Date"), and 1/36th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the third anniversary of the Vesting Commencement Date. Read SEC document
May 17, 2021 Filed May 19, 2021 16:59 UTC	PERRIGO Co plc PRGO · Entity 4516	GrantRestricted Stock Units · Derivative	6,599	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-21-000084 · wf-form4_162144352984780.xml · derivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,599 Underlying: Ordinary Shares · 6,599 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting in 3 equal annual installments beginning 17 May 2022. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting in 3 equal annual installments beginning 17 May 2022. Read SEC document
May 07, 2021 Filed May 11, 2021 18:57 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionRestricted Stock Units · Derivative	5,804	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-21-000060 · wf-form4_162075941792053.xml · derivative · entry 3 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,804 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · kind: Vesting of service-based restricted stock units granted on 7 May 2020. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 7 May 2021. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 7 May 2021. Read SEC document
May 07, 2021 Filed May 11, 2021 18:57 UTC	PERRIGO Co plc PRGO · Entity 4516	Tax withholdingOrdinary Shares	2,786	$42.96	$119,686.56	Disclosure SEC source: 0001585364-21-000060 · wf-form4_162075941792053.xml · nonDerivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,975 Read SEC document
May 07, 2021 Filed May 11, 2021 18:57 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionOrdinary Shares	5,804	$42.96	$249,339.84	Disclosure SEC source: 0001585364-21-000060 · wf-form4_162075941792053.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of service-based restricted stock units granted on 7 May 2020. Read SEC document
April 23, 2021 Filed Apr 27, 2021 20:13 UTC	PPD, Inc. PPD · Entity 15247	GrantCommon Stock	2,164	$0.00	$0.00	Disclosure SEC source: 0001628280-21-007732 · wf-form4_161955435895015.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,487 F1 · kind: Represents a grant of restricted stock units which will vest on the earlier of the one-year anniversary of the grant date and the date of the next regularly scheduled annual meeting of stockholders of the issuer, subject to continued service through the vesting date. Read SEC document
March 25, 2021 Filed Mar 29, 2021 23:47 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantOption to Purchase Common Stock (Right to Buy) · Derivative	22,107	$0.00 Strike: $7.71	$0.00	Disclosure SEC source: 0001123292-21-000566 · edgar.xml · derivative · entry 3 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,107 Underlying: Common Stock · 22,107 shares Expires 2031-03-25 Read SEC document
March 25, 2021 Filed Mar 29, 2021 23:47 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantRestricted Stock Units · Derivative	16,212	$0.00	$0.00	Disclosure SEC source: 0001123292-21-000566 · edgar.xml · derivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,212 Underlying: Common Stock · 16,212 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Precigen Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in full on March 25, 2022. F3 · derivative.expiration_date: The restricted stock units vest in full on March 25, 2022. Read SEC document
March 25, 2021 Filed Mar 29, 2021 23:47 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantCommon Stock	8,949	$7.71	$68,996.79	Disclosure SEC source: 0001123292-21-000566 · edgar.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,209 F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $69,000. Read SEC document
March 13, 2021 Filed Mar 16, 2021 20:34 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionRestricted Stock Units · Derivative	62,189	$0.00	$0.00	Disclosure SEC source: 0001123292-21-000486 · edgar.xml · derivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,189 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen, Inc. common stock. F2 · derivative.exercise_date: The RSUs vested in full on March 13, 2021. F2 · derivative.expiration_date: The RSUs vested in full on March 13, 2021. Read SEC document
March 13, 2021 Filed Mar 16, 2021 20:34 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionCommon Stock	62,189	Not disclosed	Not disclosed	Disclosure SEC source: 0001123292-21-000486 · edgar.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen, Inc. common stock. Read SEC document
December 02, 2020 Filed Feb 12, 2021 21:15 UTC	PPD, Inc. PPD · Entity 15247	GiftCommon Stock	18,500	$0.00	$0.00	Disclosure SEC source: 0000899243-21-006290 · doc5.xml · nonDerivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 18,500 F1 · kind: Represents a transfer to a family trust for estate planning purposes. Read SEC document
December 02, 2020 Filed Feb 12, 2021 21:15 UTC	PPD, Inc. PPD · Entity 15247	GiftCommon Stock	18,500	$0.00	$0.00	Disclosure SEC source: 0000899243-21-006290 · doc5.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,323 F1 · kind: Represents a transfer to a family trust for estate planning purposes. Read SEC document
June 11, 2020 Filed Jun 15, 2020 20:26 UTC	vTv Therapeutics Inc. VTVT · Entity 6614	GrantDirector stock option (right to buy) · Derivative	15,000	$2.65 Strike: $2.65	$39,750.00	Disclosure SEC source: 0001562180-20-004482 · primarydocument.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,121 Underlying: Class A common stock · 15,000 shares Expires 2030-06-11 F1 · derivative.exercise_date: The option vests in monthly equal installments over the three year period beginning on June 11, 2020. Read SEC document
May 21, 2020 Filed May 22, 2020 20:41 UTC	SIGA TECHNOLOGIES INC SIGA · Entity 6205	Exercise / conversionRestricted Stock Units · Derivative	15,000	$0.00	$0.00	Disclosure SEC source: 0001140361-20-012324 · form4.xml · derivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $.0001 per share · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") converts into one share of common stock of SIGA Technologies, Inc. on a one for one basis. F2 · derivative.exercise_date: The RSUs were granted on May 21, 2019, and vested on the first anniversary of such date. F2 · derivative.expiration_date: The RSUs were granted on May 21, 2019, and vested on the first anniversary of such date. Read SEC document
May 21, 2020 Filed May 22, 2020 20:41 UTC	SIGA TECHNOLOGIES INC SIGA · Entity 6205	Exercise / conversionCommon Stock, Par Value $.0001 Per Share	15,000	$0.00	$0.00	Disclosure SEC source: 0001140361-20-012324 · form4.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 15, 2020 Filed May 20, 2020 00:39 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionRestricted Stock Units · Derivative	6,054	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-20-000061 · wf-form4_158993517190025.xml · derivative · entry 3 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,054 shares Expires 2020-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · kind: Vesting of service-based restricted stock units granted on May 15, 2019. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document
May 15, 2020 Filed May 20, 2020 00:39 UTC	PERRIGO Co plc PRGO · Entity 4516	Tax withholdingOrdinary Shares	2,906	$52.76	$153,320.56	Disclosure SEC source: 0001585364-20-000061 · wf-form4_158993517190025.xml · nonDerivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,957 Read SEC document
May 15, 2020 Filed May 20, 2020 00:39 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionOrdinary Shares	6,054	$52.76	$319,409.04	Disclosure SEC source: 0001585364-20-000061 · wf-form4_158993517190025.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of service-based restricted stock units granted on May 15, 2019. Read SEC document
May 13, 2020 Filed May 15, 2020 20:49 UTC	PPD, Inc. PPD · Entity 15247	GrantCommon stock	3,728	$0.00	$0.00	Disclosure SEC source: 0000899243-20-013239 · doc4.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,823 F1 · kind: Represents a grant of restricted stock units which will vest on the earlier of the one-year anniversary of the grant date and the date of the next regularly scheduled annual meeting of stockholders of the issuer, subject to continued service through the vesting date. Read SEC document
May 07, 2020 Filed May 11, 2020 20:56 UTC	PERRIGO Co plc PRGO · Entity 4516	GrantRestricted Stock Units · Derivative	5,804	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-20-000055 · wf-form4_158923057614804.xml · derivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,804 Underlying: Ordinary Shares · 5,804 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 7 May 2021. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 7 May 2021. Read SEC document
March 13, 2020 Filed Mar 17, 2020 22:32 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantOption to Purchase Common Stock (Right to Buy) · Derivative	96,324	$0.00 Strike: $2.01	$0.00	Disclosure SEC source: 0001123292-20-000569 · edgar.xml · derivative · entry 3 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,324 Underlying: Common Stock · 96,324 shares Expires 2030-03-13 Read SEC document
March 13, 2020 Filed Mar 17, 2020 22:32 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantRestricted Stock Units · Derivative	62,189	$0.00	$0.00	Disclosure SEC source: 0001123292-20-000569 · edgar.xml · derivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,189 Underlying: Common Stock · 62,189 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Precigen, Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in full on March 13, 2021. F3 · derivative.expiration_date: The restricted stock units vest in full on March 13, 2021. Read SEC document
March 13, 2020 Filed Mar 17, 2020 22:32 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantCommon Stock	34,328	$2.01	$68,999.28	Disclosure SEC source: 0001123292-20-000569 · edgar.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,071 F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $69,000. Read SEC document
March 10, 2020 Filed Mar 11, 2020 20:12 UTC	vTv Therapeutics Inc. VTVT · Entity 6614	Exercise / conversionRestricted Stock Units · Derivative	11,667	$0.00	$0.00	Disclosure SEC source: 0001562180-20-002397 · primarydocument.xml · derivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 11,667 shares Expires 2020-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of vTv Therapeutics Inc. Class A Common Stock F3 · derivative.exercise_date: The restricted stock units were granted on March 10, 2017 and vest in three equal installments beginning March 10, 2018. Read SEC document
March 10, 2020 Filed Mar 11, 2020 20:12 UTC	vTv Therapeutics Inc. VTVT · Entity 6614	Exercise / conversionClass A Common Stock	11,667	$0.00	$0.00	Disclosure SEC source: 0001562180-20-002397 · primarydocument.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of Class A common stock issued upon vesting of 33.33% of the restricted stock units granted March 10, 2017. Read SEC document
March 08, 2020 Filed Mar 10, 2020 20:17 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionRestricted Stock Units · Derivative	24,703	$0.00	$0.00	Disclosure SEC source: 0001123292-20-000536 · edgar.xml · derivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,703 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F2 · derivative.exercise_date: The restricted stock units vested in full on March 8, 2020. F2 · derivative.expiration_date: The restricted stock units vested in full on March 8, 2020. Read SEC document
March 08, 2020 Filed Mar 10, 2020 20:17 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionCommon Stock	24,703	Not disclosed	Not disclosed	Disclosure SEC source: 0001123292-20-000536 · edgar.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. Read SEC document
February 10, 2020 Filed Feb 12, 2020 21:17 UTC	PPD, Inc. PPD · Entity 15247	PurchaseCommon stock	18,500	$27.00	$499,500.00	Disclosure SEC source: 0000899243-20-004253 · doc4.xml · nonDerivative · entry 3 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,095 F2 · price: Shares were acquired in a directed share program in connection with the Issuer's initial public offering. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.